Market Closed

INAB
IN8bio
$ 0.8200
-0.04%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

IN8bio News

Latest IN8bio Stock News & INAB Headlines

IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone
2 months ago | defenseworld.net
IN8bio to Present at Sidoti Small-Cap Virtual Conference
2 months ago | globenewswire.com
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
2 months ago | globenewswire.com
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
5 months ago | zacks.com
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
5 months ago | globenewswire.com
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
5 months ago | globenewswire.com
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
6 months ago | globenewswire.com
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
6 months ago | globenewswire.com
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 months ago | globenewswire.com
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
8 months ago | defenseworld.net
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

INAB
IN8bio
$ 0.8200
-0.04%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago